Turning down the volume: advancing microsampling within bioanalysis
Tuesday 31 March 2026
07:00 [PDT] 10:00 [EDT] 15:00 [BST]
Microsampling necessity, challenges and advancements in preclinical and clinical bioanalysis.
Mircosampling in both preclinical and clinical drug development can enhance patient experience, support the 3R aims, broaden clinical trial diversity via decentralized clinical trials, and help assess bioanalytical drug effects more frequently. While the benefits of microsampling are very compelling, challenges of sample integrity, capillary vs venous blood samples, bridging studies, and regulatory acceptance have historically been a barrier to industry-wide adoption. In this webinar, we will review the trends, challenges, approaches and advancements of microsampling within Labcorp Bioanalytical Services, as well as predictions about the future of microsampling for bioanalysis.
Can’t see the form below? Register for the webinar here.
What will you learn?
- Evolving trends supporting the need for microsampling in preclinical and clinical bioanalysis.
- Challenges of microsampling in preclinical/clinical bioanalysis across small and large molecules, as well as molecular modalities.
- Approaches and advancements in microsampling across a wide variety of modalities.
- Thoughts about the future of microsampling within bioanalysis.
Who this may interest?
- Pharma developers and researchers working to incorporate microsampling into preclinical and clinical drug development studies.
- Biopharmaceutical scientists involved in drug development and testing in preclinical and clinical phases.
- Bioanalytical chemists supporting preclinical and clinical MD/MV and ongoing study support.
Speakers
James Tunaley, PhD
Study Director & Scientist, Molecular Bioanalysis
Labcorp Bioanalytical Services
Dr James Tunaley has more than a decade of academic research and industrial lab experience in multiple fields, including genomics, genetic engineering, analytical chemistry, molecular biology, cell-based assays and protein expression and purification. He has expertise in supporting clients’ cell and gene therapy molecules through the preclinical and clinical stages of development with projects spanning GLP, GCP and GMP regulations. At Labcorp Bioanalytical Services, he is responsible for the scientific oversight of method development and validation using a variety of techniques across the field of molecular biology and beyond. He earned his PhD in Structural Biology and master’s in Chemistry from the University of York (UK).
Alexandra Bushby
Method Development Scientist, LC–MS
Labcorp Bioanalytical Services
Alexandra Bushby graduated with a degree in Biochemistry and is currently completing a master’s in Biopharmaceutical Development. She spent the past 10 years at Labcorp working in small molecule bioanalysis, specializing in LC–MS/MS and a wide range of extraction techniques. She began in sample analysis, progressed through method validation, and now serves as a Technical Specialist. She has extensive experience working with a diverse array of compounds, including chiral molecules and oligonucleotides across numerous biological matrices and tissues. She also has hands on expertise in patient-centric sampling approaches, including Mitra® tips, Capitainer and capillary microsampling.
In association with
